In an exclusive interview to CNBC-TV18, Kiran Mazumdar Shaw of Biocon says that the breakup with Pfizer will not have any short-term impact on revenues for either company, but will reflect in the fourth quarter financials.
first published: Mar 13, 2012 10:50 am
A collection of the most-viewed Moneycontrol videos.
Live: Nifty reclaims 25,300, registers over 1% gain this week | Closing Bell
Live: Will Nifty bulls aim to break 25,250 after strong TCS Q2? | Opening Bell
TCS Q2 Earnings Live: Margin, Revenue Beat Street Estimates
Live: Nifty reclaims 25,100 ahead of TCS Q2 results; pharma, metals shine | Closing Bell
